22 Mar NOVACYT SIGNS ASSAY DEVELOPMENT CONTRACT FOR DIAGNOSIS OF RESPIRATORY INFECTIONS WITH GENEPOC
Posted at 07:00h in Board, Novacyt Group, Products
Further validation of Novacyt’s expertise in
developing assays for clinical applications
Novacyt Signs Assay Development Contract for Diagnosis of Respiratory Infections with GenePOC
Paris, France and Camberley, UK – 22 March 2018 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, today announces its molecular testing division, Primerdesign, has entered into a clinical assay development contract with GenePOC Inc., a Canada-based company and member of the Debiopharm Group™, which specialises in the development and manufacture of molecular diagnostic devices for the detection of infectious diseases closer to the patient.